MedTrace Logo

Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients

NCT04372355 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-10-22

No results posted yet for this study

Summary

Study in adult Diabetes Mellitus patients with diabetic foot ulcers and elevated HbA1c who will receive standard wound treatment in combination with adjuvant therapy WF10 to compare the change of HbA1c levels at baseline and after treatment.

Conditions

  • Diabetic Foot Ulcer (DFU)
  • Uncontrolled Diabetes With Foot Ulcer

Interventions

DRUG

WF10

WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.

Sponsors & Collaborators

  • Oxo Chemie(Thailand) Co.,Ltd.

    collaborator UNKNOWN

  • Altermed Co.,Ltd.

    collaborator UNKNOWN

  • Srinakharinwirot University

    lead OTHER

Principal Investigators

  • Narongchai Yingsakmongkol, MD, FRCST · Srinakharinwirot University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2020-04-30
Completion
2020-06-19

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04372355 on ClinicalTrials.gov